Efficacy and safety of rivaroxaban for anticoagulant therapy in elderly patients with atrial fibrillation
10.3969/j.issn.1673-9701.2025.07.014
- VernacularTitle:利伐沙班用于高龄心房颤动患者抗凝治疗的有效性和安全性研究
- Author:
Yanxian LAN
1
;
Haipeng LU
1
;
Cong LYU
1
;
Yuxin ZENG
1
;
Xiu LUO
1
Author Information
1. 广西壮族自治区民族医院/广西医科大学附属民族医院药学部,广西南宁 530001
- Publication Type:Journal Article
- Keywords:
Rivaroxaban;
Atrial fibrillation;
Anticoagulation effect;
Safety
- From:
China Modern Doctor
2025;63(7):59-62
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of rivaroxaban in elderly patients with atrial fibrillation.Methods The cases datas of 236 elderly patients with atrial fibrillation hospitalized in Minzu Hospital of Guangxi Zhuang Autonomous Region from July 2022 to September 2023 were retrospectively analyzed.According to the use of anticoagulant drugs,they were divided into rivaroxaban group(148 cases)and warfarin group(88 cases).New thrombosis,bleeding events and all-cause death during hospitalization were compared between two groups.Logistic regression and multi-factor Cox regression analysis were used to investigate the influencing factors of new thrombus,hemorrhage and all-cause death.Results The proportion of antiplatelet drugs and platelet count in rivaroxaban group were significantly higher than those in warfarin group,and thrombin time,prothrombin time and international standardized ratio were significantly lower than those in warfarin group(P＜0.05).Before and after adjusting for confounders,there were no significant differences in the risk of new thrombosis,bleeding events and all-cause death between two groups(P＞0.05).Multivariate Cox regression analysis showed that combined use of non steroidal antiinflammatory drug and low-dose rivaroxaban were risk factors for death in elderly patients with atrial fibrillation(P＜0.05).Conclusion The efficacy and safety of rivaroxaban in elderly patients with atrial fibrillation are not inferior to warfarin.
